$A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma$

A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

# Objective To evaluate the cost-effectiveness of brentuximab vedotin in patients with R/R sALCL from a UK NHS perspective. # Methods A partitioned survival model used clinical outcomes for brentuximab vedotin from the pivotal phase-2 single-arm trial of brentuximab vedotin in 58 patients with R/R...

Full description

Saved in:

Bibliographic Details
Main Authors:	Margaret Hux, Denise Zou, Esprit Ma, Peter Sajosi, Andreas Engstrom, Ross Selby, Eugene Benson, Andrew Briggs, Vijayveer Bonthapally
Format:	Article
Language:	English
Published:	Columbia Data Analytics, LLC 2016-10-01
Series:	Journal of Health Economics and Outcomes Research
Online Access:	https://doi.org/10.36469/9820
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The Use of Brentuximab Vedotin in Relapsed/Refractory Hodgkin’s Lymphoma in the Kransnodar Region
by: OD Serdyuk, et al.
Published: (2018-01-01)

Brentuximab Vedotin: New Possibilities for Treatment of Relapses and Refractory Hodgkin’s Lymphomas
by: EA Demina
Published: (2015-10-01)

COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA
by: G. R. Khachatryan, et al.
Published: (2016-04-01)

Brentuximab vedotin (Adcetris®) in therapy of system anaplastic large cell lymphoma. Case report
by: A. A. Semenova, et al.
Published: (2019-01-01)

The Benefit of Brentuximab Vedotin and Checkpoint Inhibitors in Relapsed/Refractory Hodgkin Lymphoma: A Single-Center Retrospective Study
by: Diana-Marina FORTOES, et al.
Published: (2025-06-01)

Brentuximab vedotin in children and adolescents with Hodgkin’s lymphoma and anaplastic large cell lymphoma – literature review and own experience
by: N. V. Myakova, et al.
Published: (2016-03-01)

PRIMARY PALATAL ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA: RARITY TREATED SUCCESSFULLY WITH BRENTUXIMAB VEDOTIN
by: Müjgan Çözeli, et al.
Published: (2024-12-01)

Pharmacoeconomic analysis of therapy with brentuximab vedotin, nivolumab and pembrolizumab in patients with relapsed Hodgkin’s lymphoma
by: N. A. Avxentyev, et al.
Published: (2020-12-01)

PHARMACOECONOMIC ANALYSIS OF BRENTUXIMAB VEDOTIN THERAPY IN RELAPSED OR REFRACTORY CD30+ SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA IN PATIENTS OVER 18 YEARS OF AGE: HEALTH BUDGET IMPACT ANALYSIS
by: A. S. Kolbin, et al.
Published: (2017-05-01)

Cost-effectiveness of Brentuximab Vedotin plus chemotherapy as frontline treatment of systemic anaplastic large cell lymphoma in Italy
by: Andrea Marcellusi, et al.
Published: (2025-04-01)

Retreatment with brentuximab vedotin for discordant peripheral T-cell lymphomas
by: Gen Hasegawa, et al.
Published: (2025-01-01)

Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature
by: Wilfred Delacruz, et al.
Published: (2016-01-01)

Assessment of the Tolerability and Optimal Dosing of the Combination of Brentuximab Vedotin and Lenalidomide in Patients With Relapsed or Refractory T‐cell Lymphoma: Results of a Single‐centre Phase 1 Dose‐escalation Study
by: Carrie van der Weyden, et al.
Published: (2025-06-01)

Hodgkin’s Lymphoma after Autologous Stem-Cell Transplantation: Effective Consolidation with Brentuximab Vedotin
by: Adrian Schmidt
Published: (2020-11-01)

Therapeutic potential of brentuximab vedotin in breast cancer and lymphoma via targeted apoptosis and gene regulation
by: Abeer Ezzat, et al.
Published: (2025-01-01)

Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up
by: Eva Domingo-Domènech, et al.
Published: (2025-08-01)

SUCCESSFUL USE OF BRENTUXIMAB VEDOTIN IN THE TREATMENT OF PROGRESSIVE PERIPHERAL UNSPECIFIED T-CELL LYMPHOMA IN AN ELDERLY FEMALE PATIENT
by: L. G. Gorenkova, et al.
Published: (2017-06-01)

Hodgkin Lymphoma Treatment With Brentuximab Vedotin in a Patient With HIV, Liver Failure, and Anemia Without Transfusion
by: Ellen Marin, et al.
Published: (2025-02-01)

Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers
by: Timothy J. Voorhees, et al.
Published: (2025-03-01)

Exceptional outcome: CD-30-positive relapsed enteropathy-associated T-cell lymphoma (EATL) treated with brentuximab vedotin alone, showing significant improvement in weight and albumin levels in Type II refractory coeliac disease: a case report
by: Kainat Memon, et al.
Published: (2025-07-01)

Frontline brentuximab vedotin-based therapy for newly diagnosed classical Hodgkin lymphoma: a meta-analysis of randomized controlled trials
by: Yue Yang, et al.
Published: (2025-07-01)

Signal mining and analysis of adverse events of Brentuximab Vedotin base on FAERS and JADER databases.
by: Feilong Tan, et al.
Published: (2025-01-01)

Pneumocystis jirovecii Pneumonia during Brentuximab Vedotin Therapy: A Case Report and Literature Review
by: Aliana Meneses Ferreira, et al.
Published: (2019-01-01)

Real-world experiences with brentuximab vedotion-based regimens in systemic anaplastic large cell lymphoma: a multi-center retrospective study
by: Zhiqiang Zhao, et al.
Published: (2025-01-01)

TREATMENT OF RELAPSE AND REFRACTORY HODGKIN LYMPHOMA
by: E. A. Baryakh
Published: (2017-06-01)

Effectiveness and Safety of Polatuzumab Vedotin Plus an Anti‐CD20 Monoclonal Antibody (Rituximab or Obinutuzumab) and Zanubrutinib in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma
by: Yian Zhang, et al.
Published: (2025-08-01)

Comparative clinical and economic assessment of polatuzumab vedotin therapy in combination with bendamustine and rituximab for adult transplantation-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma
by: I. N. Dyakov, et al.
Published: (2022-07-01)

Treatment of Relapsed and Refractory Hodgkin’s Lymphoma in Children
by: NS Kulichkina, et al.
Published: (2016-01-01)

Cutaneous involvement of systemic anaplastic lymphoma kinase-positive anaplastic large cell lymphoma
by: Tanmoy Kumar Mandal, et al.
Published: (2020-01-01)

Alectinib Monotherapy in Isolated Central Nervous System Relapse of ALK-Positive Anaplastic Large Cell Lymphoma
by: Julian Verran, et al.
Published: (2022-01-01)

Central nervous system relapse of primary cutaneous anaplastic large cell lymphoma: A case report
by: Satoshi Mitsuyuki, et al.
Published: (2025-04-01)

Overcoming Resistance in Relapsed Anaplastic Large-Cell Lymphoma, ALK-Positive (Literature Review and Clinical Experience)
by: YuE Vinogradova, et al.
Published: (2019-03-01)

Refractory/Relapsed Classic Hodgkin Lymphoma Mimicking Disseminated Tuberculosis
by: Mohamed Nazem Alibrahim, et al.
Published: (2025-05-01)

Mosunetuzumab for relapsed or refractory follicular lymphoma: a case study
by: Ya. V. Krylova, et al.
Published: (2024-09-01)

Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review
by: Roberta Fedele, et al.
Published: (2015-01-01)

A rare case of circulating anaplastic lymphoma kinase-negative anaplastic large cell lymphoma
by: Radu Chiriac, et al.
Published: (2025-01-01)

Outcomes of immune checkpoint inhibitor rechallenge in relapsed/refractory Hodgkin lymphoma
by: Yoshito Nishimura, et al.
Published: (2025-08-01)

A Rare Case of Anaplastic Lymphoma Kinase-negative Anaplastic Large Cell Lymphoma Presenting as Right Heart Failure
by: U. Harikishore, et al.
Published: (2025-01-01)

Nasal primary anaplastic lymphoma kinase-negative anaplastic large cell lymphoma with fungal infection: A case report
by: Yun Huang, et al.
Published: (2025-05-01)

Nivolumab for relapsed and refractory classical Hodgkin lymphoma: retrospective single center analysis
by: Magdalena Witkowska, et al.
Published: (2025-01-01)